Faculty from Johns Hopkins University School of Medicine have teamed up with EXoPERT, a company specializing in molecular diagnostics, to work on EXoPERT’s exosome-based Multi-Cancer Early Detection (MCED) platform. This innovative collaboration aims to enhance the accuracy and clinical utility of EXoPERT’s technology for the early detection of multiple cancer types.
Johns Hopkins University researcher Jonathan Dudley, MD, and EXoPERT Principal Investigator Yeonho Choi, PhD, will lead the effort to validate EXoPERT’s exosome isolation and molecular fingerprint detection technology.
Dudley is a physician-scientist and assistant professor of pathology, oncology, and urology at the Johns Hopkins University School of Medicine. With expertise in cutting-edge molecular diagnostics, Dudley focuses on developing novel methods for the detection and classification of cancer. The collaboration with EXoPERT builds on groundbreaking work to validate and improve an exosome-based Multi-Cancer Early Detection platform, positioning him to push the boundaries of precision oncology and improve outcomes for cancer patients worldwide.
Choi believes that combining EXoPERT’s software and hardware technology with Dudley’s expertise in molecular diagnostics can lead to effective and scalable early cancer detection worldwide.
EXoPERT’s MCED platform is designed to isolate exosomes from a single blood sample and analyze their molecular fingerprints using Raman spectroscopy. This approach enables signal analysis for the detection of multiple cancer types, with numerous applications for early cancer interventions. Precision diagnostics for early cancer detection could play a pivotal role in saving lives through timely intervention and improved clinical outcomes.
The JHTV Corporate Partnerships team is committed to facilitating industry research collaborations with Johns Hopkins researchers to address society’s unmet medical needs. Connect with the team here.